10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2011

or

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number: 000-52530

Omni Bio Pharmaceutical, Inc.

(Exact Name of Registrant as Specified in its Charter)

Colorado	20-8097969
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

5350 South Roslyn, Suite 430, Greenwood Village, CO 80111
(Address of principal executive offices, including zip code)

(303) 867-3415
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o	Accelerated filer þ	Non-accelerated filer o	Smaller reporting company o
		(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ

The number of shares outstanding of the registrant’s common stock as of November 1, 2011 was 32,018,396.

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY

TABLE OF CONTENTS

	Page
PART I: FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Balance Sheets — September 30, 2011 and March 31, 2011 (unaudited)		2
Consolidated Statements of Operations — For the three months ended September 30, 2011 and 2010 (unaudited)		3
Consolidated Statements of Operations — For the six months ended September 30, 2011 and 2010, and February 28, 2006 (Inception) through September 30, 2011 (unaudited)		4
Consolidated Statements of Stockholders’ Equity — As of and for the six months ended September 30, 2011 (unaudited)		5
Consolidated Statements of Cash Flows — For the six months ended September 30, 2011 and 2010, and February 28, 2006 (Inception) through September 30, 2011 (unaudited)		6
Notes to Consolidated Financial Statements (unaudited)		7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		13
Item 3. Quantitative and Qualitative Disclosures About Market Risk		18
Item 4. Controls and Procedures		18
PART II: OTHER INFORMATION
Item 1. Legal Proceedings		19
Item 1A. Risk Factors		19
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		19
Item 3. Defaults Upon Senior Securities		19
Item 5. Other Information		19
Item 6. Exhibits		20
Signatures		21
Exhibit 31.1
Exhibit 31.2
Exhibit 32.1
EX-101 INSTANCE DOCUMENT
EX-101 SCHEMA DOCUMENT
EX-101 CALCULATION LINKBASE DOCUMENT
EX-101 LABELS LINKBASE DOCUMENT
EX-101 PRESENTATION LINKBASE DOCUMENT
EX-101 DEFINITION LINKBASE DOCUMENT

Part I. FINANCIAL INFORMATION

Item 1. Financial Statements.

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY
(A Development Stage Company)

CONSOLIDATED BALANCE SHEETS

	September 30, 2011			March 31, 2011
	(Unaudited)			(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	938,508		$	301,765
Other current assets		50,958			43,541
Total current assets		989,466			345,306
Equity investment in related party		1,664,072			—
Intangible assets, net		59,289			61,931
Total long-term assets		1,723,361			61,931
TOTAL ASSETS		2,712,827		$	407,237
LIABILITIES & STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	75,954		$	41,763
Amount due under sponsored research agreement		140,223			—
Accrued research and development costs		130,389			44,736
Accrued liabilities		56,250			116,500
Amounts due to related parties		3,750			3,750
Total current liabilities		406,566			206,749
Commitments and Contingencies (Notes 1 and 3)
Stockholders’ equity:
Preferred stock, $0.10 par value, 5,000,000 shares authorized, -0- shares issued and outstanding		—			—
Common stock, $0.001 par value; 200,000,000 shares authorized; 32,018,396 and 28,980,496 shares issued and outstanding, respectively		32,018			28,980
Additional paid-in capital		36,757,742			31,336,345
Deficit accumulated during the development stage		(34,483,499	)		(31,164,837	)
Total stockholders’ equity		2,306,261			200,488
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	2,712,827		$	407,237

The accompanying notes are an integral part of these consolidated financial statements.

2

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY
(A Development Stage Company)

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For the Three Months Ended
	September 30,
	2011			2010
Operating expenses:
General and administrative (including share-based compensation of $919,803 and $2,376,849, respectively)	$	1,271,348		$	2,632,820
Research and development		63,743			82,889
Total operating expenses		1,335,091			2,715,709
Loss from operations		(1,335,091	)		(2,715,709	)
Non-operating income (expenses):
Equity in loss of related party		(335,928	)		—
Interest income (expense), net		970			1,278
Charges for modifications to warrants		(140,959	)		—
Total non-operating income (expenses)		(475,917	)		1,278
Net loss	$	(1,811,008	)	$	(2,714,431	)
Basic and diluted net loss per share	$	(0.06	)	$	(0.10	)
Weighted average shares outstanding — basic and diluted		31,920,918			28,042,982

The accompanying notes are an integral part of these consolidated financial statements.

3

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY
(A Development Stage Company)

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

							February 28, 2006
	For the Six Months Ended						(Inception) through
	September 30,						September 30, 2011
	2011			2010
Operating expenses:
General and administrative (including share-based compensation of $1,839,606, $4,850,902 and $16,167,157, respectively)	$	2,587,548		$	5,367,501		$	20,571,364
Research and development		255,875			82,889			1,965,885
License fee — related party		—			—			5,615,980
Charge for common stock issued pursuant to license agreements		—			—			763,240
Total operating expenses		2,843,423			5,450,390			28,916,469
Loss from operations		(2,843,423	)		(5,450,390	)		(28,916,469	)
Non-operating income (expenses):
Equity in loss of related party		(335,928	)		—			(335,928	)
Interest income (expense), net		1,648			3,634			(50,745	)
Accretion expense on notes payable — related party		—			(3,000	)		(56,125	)
Charges for warrants issued in merger — related parties		—			—			(1,948,237	)
Charge for warrants issued in private placement — related parties		—			—			(403,350	)
Charges for modifications to warrants		(140,959	)		—			(2,772,645	)
Total non-operating income (expenses)		(475,239	)		634			(5,567,030	)
Net loss	$	(3,318,662	)	$	(5,449,756	)	$	(34,483,499	)
Basic and diluted net loss per share	$	(0.11	)	$	(0.19	)
Weighted average shares outstanding — basic and diluted		30,748,871			28,022,974

4

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY
(A Development Stage Company)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

											Deficit
											Accumulated
									Additional		During			Total
									Paid-in		Development			Stockholders’
	Preferred Stock				Common Stock				Capital		Stage			Equity
	Shares		Amount		Shares		Amount
Balances at March 31, 2011		—	$	—		28,980,496	$	28,980	$	31,336,345	$	(31,164,837	)	$	200,488
Common stock and common stock purchase warrants sold in private placement offering, net of offering costs of $353,505 (June and August 2011 at $1.25 per unit)						3,037,900		3,038		3,440,832					3,443,870
Share-based compensation										1,839,606					1,839,606
Charge for modification to common stock purchase warrants sold in private placement offering in December 2009 and January 2010)										140,959					140,959
Net loss												(3,318,662	)		(3,318,662	)
Balances at September 30, 2011 (unaudited)		—	$	—		32,018,396	$	32,018	$	36,757,742	$	(34,483,499	)	$	2,306,261

The accompanying notes are an integral part of these consolidated financial statements.

5

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY
(A Development Stage Company)

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

							February 28, 2006
	For the Six Months Ended						(Inception) Through
	September 30,						September 30, 2011
	2011			2010
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(3,318,662	)	$	(5,449,756	)	$	(34,483,499	)
Adjustments used to reconcile net loss to net cash used in operating activities:
Equity in loss of related party		335,928			—			335,928
Charge for warrant issued for purchase of license — related party		—			—			5,590,980
Common stock issued pursuant to license agreements		—			—			763,240
Share-based compensation		1,839,606			4,850,902			16,167,157
Charge for warrants issued in merger transaction - related parties		—			—			1,948,237
Charge for warrants issued in private placement transaction — related parties		—			—			403,350
Charges for modifications to warrants		140,959			—			2,772,645
Accretion expense — related parties		—			3,000			56,125
Depreciation and amortization		2,642			3,440			25,588
Contributed rent		—			—			19,740
Loss on disposal of equipment		—			—			2,444
Changes in operating assets and liabilities:
Prepaid clinical trial fee		—			(365,000	)		—
Other current assets		(7,417	)		(29,129	)		(53,057	)
Accounts payable		34,191			(37,985	)		282,131
Accrued liabilities		(60,250	)		(31,237	)		(255,574	)
Accrued research and development costs		85,653			—			130,389
Amount due under sponsored research agreement		140,223			—			140,223
Amounts due to related parties		—			(375	)		207,632
Net cash used in operating activities		(807,127	)		(1,056,140	)		(5,946,321	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Equity investment in related party		(2,000,000	)		—			(2,000,000	)
Cash proceeds from reverse merger transactions		—			—			11,750
Purchase of licenses		—			—			(7,423	)
Purchase of property and equipment		—			—			(35,401	)
Net cash used in investing activities		(2,000,000	)		—			(2,031,074	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from the sale of common stock and warrants		3,443,870			—			7,729,815
Proceeds from the issuance of notes payable to related party		—			—			825,000
Proceeds from the sale of common stock warrants		—			—			125,000
Proceeds from the exercise of common stock warrants		—			—			236,088
Net cash provided by financing activities		3,443,870			—			8,915,903
Net increase (decrease) in cash and cash equivalents		636,743			(1,056,140	)		938,508
Cash and cash equivalents at beginning of period		301,765			1,802,366			—
Cash and cash equivalents at end of period	$	938,508		$	746,226		$	938,508

6

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY
(A Development Stage Company)

Notes to Consolidated Financial Statements (Unaudited)

NOTE 1 — OVERVIEW AND BASIS OF PRESENTATION

Overview

Omni Bio Pharmaceutical, Inc. (“Omni”) is the licensee of patents and patent applications related to novel compositions of matter and methods of use for an existing FDA approved drug, Alpha-1 antitrypsin (“AAT”). We currently hold three licenses with the Regents of the University of Colorado (“RUC”) in the areas of cellular transplantation, bacterial disorders and viral disorders. Our current licensed patent portfolio with RUC is comprised of 3 issued patents and 24 patent applications. We also hold a fourth license to a patent application for the treatment of diabetes with a privately-held company, Bio Holding, Inc. (“Bio Holding”).

We are currently focusing on three indications for treatment using AAT: diabetes, complications due to graft rejection, also referred to as graft versus host disease (“GVHD”), and islet transplantation. To date, our business efforts have been largely dedicated to pursuing additional capital to fund Sponsored Research Agreements (“SRAs”) with the University of Colorado Denver (“UCD”) in indications covered under the license agreements with RUC and Bio Holding and to fund a human clinical trial in Type 1 diabetes. Since inception, we have not generated any revenues from our operations.

Basis of Presentation

The accompanying unaudited consolidated financial statements are comprised of Omni and its wholly-owned subsidiary, Omni Bio Operating, Inc., and have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the unaudited consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements, and reflect all adjustments, consisting only of normal, recurring adjustments, necessary for a fair presentation in accordance with US GAAP. The results of operations for interim periods presented are not necessarily indicative of the operating results for the full year. These unaudited consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2011 (the “2011 Form 10-K”). The balances as of March 31, 2011 are derived from our audited consolidated financial statements.

Except as the context otherwise requires, the terms “Company,” “we,” “our” or “us” means Omni and its wholly-owned subsidiary, Omni Bio Operating, Inc. (“Omni Bio”).

Going Concern

The accompanying financial statements have been prepared in conformity with US GAAP, which contemplate our continuation as a going concern, whereby the realization of assets and liquidation of liabilities are in the ordinary course of business. However, the report of our independent registered public accounting firm on our consolidated financial statements, as of and for the year ended March 31, 2011, contains an explanatory paragraph expressing substantial doubt as to our ability to continue as a going concern. The “going concern” qualification resulted from, among other things, our development-stage status, no revenue recognized since inception, our net losses since inception and the outstanding and currently anticipated contractual commitments for research and development efforts and clinical trials. As of September 30, 2011, we remain a development stage company and our focus continues to be on raising capital to fund current operations and research and development efforts on AAT indications. As of September 30, 2011, we had a deficit accumulated from inception of $34.5 million, which included total non-cash charges from inception of approximately $27.8 million. These conditions raise substantial doubt as to our ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might be different should we be unable to continue as a going concern.

7

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY
(A Development Stage Company)
Notes to Consolidated Financial Statements (Unaudited)

In June and August of 2011, we completed three closings of a private placement equity offering (the “2011 Private Placement”) and raised approximately $3.44 million in net cash proceeds. See further discussion and disclosures in Note 2. We expect that the cash raised in the 2011 Private Placement will allow us to fund our operations through our fiscal year ended March 31, 2012 based on current operating levels, however, we will need to engage in additional capital raising to operate beyond that period. There is no assurance that we will be successful in raising additional capital on acceptable terms or at all. Failure to obtain additional capital may have a material adverse impact on our ability to continue our research and development efforts and fund our operating expenses beyond March 31, 2012.

Supplemental Disclosures of Non-Cash Investing and Financing Activities

	For the Six Months Ended
	September 30,
	2011		2010
Accounts payable converted to common stock	$	—	$	49,982
Note payable — related party converted to common stock	$	—	$	25,000

Recently Issued Accounting Standard Updates

We have reviewed all of the FASB’s Accounting Standard Updates through the filing date of this report and have concluded that none will have a material impact on our future consolidated financial statements.

NOTE 2 — PRIVATE PLACEMENT TRANSACTION

On June 10, 2011, we accepted subscription agreements related to the sale of “Units” in the 2011 Private Placement. Each “Unit” is comprised of one share of our common stock and one warrant to purchase one share of our common stock for a purchase price of $1.25 per Unit. Each warrant in the Unit (the “2011 Private Placement Warrants”) is exercisable at $2.00 per share until five years from the initial closing of the 2011 Private Placement. The net proceeds of the 2011 Private Placement will be used for general working capital purposes and research and development projects, and $2.0 million was used to purchase an equity interest in a private biotech company that is a related party. See further discussion in Note 6.

On June 10, 2011, we conducted the initial closing under the 2011 Private Placement, pursuant to which we entered into subscription agreements for the purchase of 2,463,900 Units for an aggregate subscription price of $3,079,875. After deducting offering expenses, including commissions and expenses paid to the placement agent, net proceeds to us from such sales totaled approximately $2,797,000. Certain of our officers and directors purchased an aggregate of 50,000 Units in the initial closing of the 2011 Private Placement.

On June 27, 2011, we conducted a second closing under the 2011 Private Placement, pursuant to which we entered into subscription agreements for the purchase of 338,000 Units for an aggregate subscription price of $422,500. After deducting offering expenses including commissions and expenses paid to the placement agent, net proceeds to us from such sales totaled approximately $378,000. Certain of our officers and directors purchased an aggregate of 50,000 Units in the second closing of the 2011 Private Placement.

On August 8, 2011, we completed the final closing for the 2011 Private Placement, pursuant to which we accepted subscription agreements for the purchase of 236,000 Units for an aggregate subscription price of $295,000. After deducting offering expenses, including commissions and expenses paid to the placement agent, net proceeds to us from such sales totaled approximately $266,000.

8

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY
(A Development Stage Company)
Notes to Consolidated Financial Statements (Unaudited)

GVC Capital LLC (“GVC Capital”) served as the placement agent for the 2011 Private Placement and earned a cash commission of 9% of the gross proceeds raised. In addition, we were obligated to sell for a nominal fee to GVC Capital, as the placement agent, warrants to purchase 9% of the total number of shares of our common stock sold in the 2011 Private Placement, which are exercisable at a price of $1.50 per share (the “2011 Private Placement PA Warrants”). The 2011 Private Placement PA Warrants expire five years from the date of the final closing of the 2011 Private Placement. We issued a total of 273,411 of 2011 Private Placement PA Warrants to GVC Capital in conjunction with the three closings of the 2011 Private Placement. Two of our directors are senior managing partners in GVC Capital.

At our option, we may call the 2011 Private Placement Warrants through June 10, 2016 by giving the holder notice of call upon 20 days written notice. Such notice may be given by us only within 10 days after our common stock has had a closing price of not less than $4.00 per share for 20 out of 30 consecutive trading days with trading volume in excess of 25,000 shares per day for that period of days.

NOTE 3 — CONTRACTUAL COMMITMENTS

Type 1 Diabetes Clinical Trial

On June 7, 2010, we executed an Investigational Site Agreement (the “ISA”), whereby we agreed to fund a two-year clinical study to evaluate AAT in the treatment of patients with Type 1 diabetes (the “Diabetes Clinical Trial”). The Diabetes Clinical Trial was initially to include 15 patients. In October 2011, we elected to reduce the size of the Diabetes Clinical Trial to 12 patients. Based on the reduction of patients, our remaining obligations for the Diabetes Clinical Trial are approximately $120,000. For the six months ended September 30, 2011, we recorded approximately $113,000 of research and development expense related to the Diabetes Clinical Trial based on four new patients infused during this period.

Viral Disorders SRA

On August 18, 2010, we entered into an SRA with RUC for UCD to perform studies to determine the biological activity of AAT as an inhibitor of influenza (the “Viral SRA”). We were required to make quarterly payments over a two-year period to UCD, which totaled approximately $440,000. As of September 30, 2011, we had paid UCD approximately $110,000.

On June 8, 2011, we gave written notice to RUC terminating the Viral SRA. In July 2011, we received acknowledgment from UCD of our termination letter related to the Viral SRA, and based on discussions related thereto, we have estimated and recorded a liability in the amount of $140,000 for settlement of all obligations due under the Viral SRA. This liability is represented as of September 30, 2011 under the caption “Amount due under sponsored research agreement” on our unaudited consolidated balance sheet included in this report.

Diabetes SRA

On September 3, 2010, we executed an SRA with UCD in the area of diabetes (the “Diabetes SRA”). The Diabetes SRA was executed pursuant to a license agreement for the treatment of diabetes (the “Diabetes License”) that we executed in 2009 with Bio Holding. The total amount due under the Diabetes SRA is $88,000, of which all has been paid as of September 30, 2011.

9

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY
(A Development Stage Company)
Notes to Consolidated Financial Statements (Unaudited)

NOTE 4 — NET LOSS PER SHARE

Basic loss per share is computed based on the weighted average number of common shares outstanding during the period presented. Diluted earnings (loss) per share is computed using the weighted average number of common shares outstanding plus the number of common shares that would be issued assuming exercise or conversion of all potentially dilutive common shares. Potentially dilutive securities are excluded from the calculation when their effect would be anti-dilutive. For all periods presented in the consolidated financial statements, all potentially dilutive securities have been excluded from the diluted share calculations as they were anti-dilutive as a result of the net losses incurred for the respective periods. Accordingly, basic shares equal diluted shares for all periods presented. As of September 30, 2011 and September 30, 2010, potentially dilutive securities were comprised of 13,934,303 and 11,557,992 common stock purchase warrants, respectively.

NOTE 5 — SHARE-BASED COMPENSATION

All equity-based awards to employees, directors and consultants are recognized in the consolidated financial statements at the fair value of the award on the grant date. During the six months ended September 30, 2011, we did not grant or issue any equity-based awards.

Share-based compensation recorded for the three and six months ended September 30, 2011 and 2010 was as follows:

	Three Months Ended September 30,				Six Months Ended September 30,
	2011		2010		2011		2010
Employees, and directors	$	919,803	$	1,316,970	$	1,839,606	$	2,731,142
Outside consultants		—		1,059,879		—		2,119,760
	$	919,803	$	2,376,849	$	1,839,606	$	4,850,902

As of September 30, 2011, there was approximately $4.8 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements that is expected to be recognized over a weighted-average period of approximately 1.7 years.

10

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY
(A Development Stage Company)
Notes to Consolidated Financial Statements (Unaudited)

A summary of activity related to warrants issued to employees, directors and consultants under share-based compensation agreements for the three months ended September 30, 2011 is as follows:

					Weighted
			Weighted		Average
			Average		Remaining
			Exercise		Contractual		Aggregate
	Shares		Price		Term (in years)		Intrinsic Value
Outstanding at March 31, 2011		3,243,000	$	1.97
Granted		—		—
Exercised		—		—
Forfeited/expired/cancelled		—		—
Outstanding at September 30, 2011		3,243,000	$	1.97		4.1	$	741,000
Vested and exercisable at September 30, 2011		2,863,000	$	1.84		4.0	$	741,000

NOTE 6 — INVESTMENT IN BIOMIMETIX PHARMACEUTICAL, INC.

On July 15, 2011 for cash consideration of $2.0 million, we purchased an equity ownership in BioMimetix Pharmaceutical, Inc. (“BioMimetix”) comprised of 250,000 shares of BioMimetix’s common stock and a warrant (the “BioM Warrant”) to purchase additional shares of BioMimetix’s common stock (together the “BioM Investment”). The BioM Warrant is immediately exercisable and expires on July 15, 2012. If the BioM Warrant is fully exercised, which will require an additional $2.0 million cash investment, we will hold an aggregate 40% equity ownership interest in BioMimetix. The BioM Warrant may be exercised in whole or in part, and if in part, our diluted equity ownership upon exercise will be calculated as follows: (Cash Consideration Paid multiplied by 15% divided by $2,000,000) plus 25%. As of September 30, 2011, we owned 28.1% of BioMimetix’s issued and outstanding shares.

Concurrent with the BioM Investment, Duke University entered into an exclusive licensing arrangement with BioMimetix (the “Duke License”), and as consideration, Duke University received 100,000 shares of BioMimetix’s common stock. BioMimetix is a recently formed biopharmaceutical corporation and, as the exclusive licensee of the Duke License, intends to develop a new class of patented compounds for the treatment of various disease and health care treatment classifications including radiation toxicity during the treatment of cancer using radiation therapy.

Dr. James Crapo, our Chief Executive Officer, is the founder and a significant shareholder of BioMimetix and serves as its CEO and as a director. Under the terms of the BioMimetix stockholders’ agreement, we have the right to appoint one individual, reasonably acceptable to Dr. Crapo, to serve on BioMimetix’s board of directors. In addition, we received certain preemptive rights to purchase additional shares of BioMimetix and other protective rights relating to the BioM Investment.

We accounted for the BioM Investment using the equity method of accounting and recorded the BioM Investment at the purchase price of $2.0 million, which was deemed to be fair value. The purchase price exceeded our pro-rata share of BioMimetix’s net assets and this difference of approximately $1.4 million was attributable to equity method goodwill, which is not amortized. For the three and six months ended September 30, 2011, we recorded a pro-rata net loss from BioMimetix of $335,928.

11

OMNI BIO PHARMACEUTICAL, INC. & SUBSIDIARY
(A Development Stage Company)
Notes to Consolidated Financial Statements (Unaudited)

For the three and six months ended September 30, 2011, BioMimetix reported the following operating results:

Loss from continuing operations	$	(1,197,051	)
Net loss and net loss attributable to investee	$	(1,195,902	)

As of September 30, 2011, BioMimetix’s balance sheet was comprised as follows:

Assets (all cash)	$	1,730,538
Liabilities	$	81,650
Stockholders’ equity	$	1,648,888

12

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

FORWARD LOOKING STATEMENTS

The following discussion contains forward-looking statements regarding us, our business, prospects and results of operations that are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those that may be anticipated by such forward-looking statements. Factors that may affect such forward-looking statements include, without limitation: our ability and the ability of BioMimetix to successfully develop new products and services for new markets; changes in law or regulatory requirements that adversely affect our ability to market our products; delays in the introduction of our products or services into the market; our ability to secure adequate financing for our operations; and our failure to keep pace with our competitors. For additional factors that may affect the validity of our forward-looking statements, see the risk facts set forth in Part I. Item 1A “Risk Factors” of our 2011 Form 10-K and Part II. Item 1A “Risk Factors” of our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2011.

When used in this report, words such as “believes,” “anticipates,” “expects,” “intends” and similar expressions are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that may subsequently arise. Readers are urged to carefully review and consider the various disclosures made by us in this report and other reports filed with the Securities and Exchange Commission (“SEC”) that attempt to advise interested parties of the risks and factors that may affect our business.

Overview

We are the licensee of applications and patents related to novel compositions of matter and methods of use for an existing FDA approved drug, Alpha-1 antitrypsin (“AAT”). We currently hold three licenses with the Regents of the University of Colorado (“RUC”) in the areas of cellular transplantation, bacterial disorders and viral disorders. Our current licensed patent portfolio with RUC is comprised of 3 issued patents and 24 patent applications. We also hold a fourth license to a patent application for the treatment of diabetes with a privately-held company, Bio Holding, Inc. (“Bio Holding”).

We are currently focusing on three indications for treatment using AAT: diabetes, complications due to graft rejection, also referred to as graft versus host disease (“GVHD”), and islet transplantation. To date, our business efforts have been largely dedicated to pursuing additional capital to fund Sponsored Research Agreements (“SRAs”) with the University of Colorado Denver (“UCD”) in indications covered under the license agreements with RUC and Bio Holding and to fund a human clinical trial in Type 1 diabetes. Since inception, we have not generated any revenues from our operations.

Current Scientific Developments

Clinical Trial on Type 1 Diabetes

On June 7, 2010, we executed an Investigational Site Agreement (the “ISA”), whereby we agreed to fund a two-year clinical study to evaluate AAT in the treatment of patients with Type 1 diabetes (the “Diabetes Clinical Trial”). The Diabetes Clinical Trial was initially to include 15 patients. In October 2011, we elected to reduce the size of the Diabetes Clinical Trial to 12 patients, all of which had completed their weekly infusions in October 2011. We are currently exploring the possibility of commencing a new Type 1 diabetes human clinical trial subject to raising additional capital through a strategic partnership or an equity capital raise.

13

Viral Disorders SRA

On August 18, 2010, we entered into an SRA with RUC for UCD to perform studies to determine the biological activity of AAT as an inhibitor of influenza (the “Viral SRA”). We were required to make quarterly payments over a two-year period to UCD, which totaled approximately $440,000. As of September 30, 2011, we had paid UCD approximately $110,000.

On June 8, 2011, we gave written notice to RUC terminating the Viral SRA. In July 2011, we received acknowledgment from UCD of our termination letter related to the Viral SRA, and based on discussions related thereto, we have estimated and recorded a liability in the amount of $140,000 for settlement of all obligations due under the Viral SRA.

Our decision to terminate the Viral SRA was made based our need to conserve cash and refocus our research and development efforts on indications that we believe are commercially feasible at this time. These indications include diabetes and cellular transplantation, which includes GVHD and islet transplantation. Further, to pursue additional research and development and potential future clinical trials in diabetes, GVHD and islet transplantation, we will most likely need to form a strategic partnership with one or more of the current AAT manufacturers, which we expect would include receiving financial support from them for AAT indications that they can most quickly commercialize. However, there can be no assurance of forming a strategic partnership, and if so, that we would receive financial funding.

Investment in BioMimetix

On July 15, 2011 and for cash consideration of $2.0 million, we purchased an equity ownership in BioMimetix Pharmaceutical, Inc. (“BioMimetix”) comprised of 250,000 shares of BioMimetix’s common stock and a warrant (the “BioM Warrant”) to purchase additional shares of BioMimetix’s common stock for cash consideration of $2.0 million (the “BioM Investment”). Concurrent with the BioM Investment, Duke University entered into an exclusive licensing arrangement with BioMimetix (the “Duke License”), and as consideration Duke University received 100,000 shares of BioMimetix’s common stock. BioMimetix is a recently formed biopharmaceutical corporation and, as the exclusive licensee of the Duke License, intends to develop a new class of patented compounds for the treatment of various disease and health care treatment classifications including radiation toxicity during the treatment of cancer using radiation therapy.

Dr. James Crapo, our Chief Executive Officer, is the founder and a significant shareholder of BioMimetix and serves as its CEO and as a director. Under the terms of the BioMimetix stockholders’ agreement, we have the right to appoint one individual, reasonably acceptable to Dr. Crapo, to serve on BioMimetix’s board of directors. In addition, we received certain preemptive rights to purchase additional shares of BioMimetix and other protective rights relating to the BioM Investment.

The BioM Warrant is immediately exercisable and expires on July 15, 2012. If the BioM Warrant is fully exercised, which will require an additional $2.0 million cash investment, we will hold an aggregate 40% equity ownership interest in BioMimetix. The BioM Warrant may be exercised in whole or in part, and if in part, our diluted equity ownership upon exercise will be calculated as follows: (Cash Consideration Paid multiplied by 15% divided by $2,000,000) plus 25%.

As of September 30, 2011, we owned 28.1% of BioMimetix’s issued and outstanding shares. We accounted for the BioM Investment using the equity method of accounting and recorded our investment at the purchase price of $2.0 million, which was deemed to be fair value. The purchase price exceeded our pro-rata share of BioMimetix’s net assets and this difference of approximately $1.4 million was attributable to equity method goodwill, which is not amortized. For the three and six months ended September 30, 2011, we recorded a pro-rata net loss from BioMimetix of $335,928.

14

Results of Operations — For the Three Months Ended September 30, 2011 Compared to the Three Months Ended September 30, 2010

The following discussion relates to our operations for the three months ended September 30, 2011 (the “September 2011 quarter”) as compared to the three months ended September 30, 2010 (the “September 2010 quarter”).

Net loss — For the September 2011 quarter, we reported a net loss of $1,811,008 as compared to a net loss of $2,714,431 for the September 2010 quarter, a decrease of $903,423. This decrease was primarily attributable to decreases in general and administrative expenses of approximately $1,361,000, of which approximately $1,457,000 of this decrease was attributable to share-based compensation. Offsetting this decrease was an increase in non-operating expenses of approximately $477,000, which is further discussed below. We have not reported any revenue since inception and it is highly likely that we will not recognize any revenue in the near term.

General and administrative expenses - General and administrative expenses for the September 2011 quarter were $1,271,348, which included $919,803 of share-based compensation, as compared to $2,632,820 in the September 2010 quarter, which included $2,376,849 of share-based compensation. As we have disclosed in prior filings, management views general and administrative expenses exclusive of share-based compensation as an important non-GAAP measure. As a development stage company, we believe that excluding the impact of share-based compensation better reflects the recurring economic characteristics of our business to shareholders and potential investors. Accordingly, excluding share-based compensation, general and administrative expenses in the September 2011 quarter were $351,545 as compared to $255,971 for the September 2010 quarter, an increase of $95,574 or approximately 37%. This increase was primarily due to increases in certain expense categories, most notably officer salary and consulting fees of approximately $65,000 due to higher headcount and legal fees for patent filings and related prosecution of approximately $42,000.

Research and development expenses — Research and development expenses for the September 2011 quarter were $63,743 as compared to $82,889 for the September 2010 quarter, a decrease of $19,146. This decrease was primarily due to a decrease of approximately $55,000 in expense related to the Viral SRA a result of terminating the Viral SRA and recording all estimated amounts due as of June 30, 2011. Offsetting this decrease was an increase in expense related to the Diabetes Clinical Trial as a result of no patient infusions occurring in the September 2010 quarter.

Non-operating expenses — Non-operating expenses for the September 2011 quarter increased $477,195 as compared to the September 2010 quarter due to expenses recorded in the September 2011 quarter for the equity loss of BioMimetix of $335,928 and a charge in the amount of $140,959 for a modification of investor warrants originally issued during the fiscal year ended March 31, 2010.

Results of Operations — For the Six Months Ended September 30, 2011 Compared to the Six Months Ended September 30, 2010

The following discussion relates to our operations for the six months ended September 30, 2011 (the “September 2011 period”) as compared to the six months ended September 30, 2010 (the “September 2010 period”).

Net loss — For the September 2011 period, we reported a net loss of $3,318,662 as compared to a net loss of $5,449,756 for the September 2010 period, a decrease of $2,131,094. This decrease was primarily attributable to decreases in general and administrative expenses of approximately $2,780,000, of which approximately $3,011,000 of this decrease was attributable to share-based compensation. Offsetting this decrease was an increase in non-operating expenses of approximately $476,000, which is further discussed below.

15

General and administrative expenses - General and administrative expenses for the September 2011 period were $2,587,548, and included $1,839,606 of share-based compensation, as compared to $5,367,501 in the September 2010 period, which included $4,850,902 of share-based compensation. As we have disclosed in prior filings and as described above, management views general and administrative expenses exclusive of share-based compensation as an important non-GAAP measure. Accordingly, excluding share-based compensation, general and administrative expenses in the September 2011 period were $747,942 as compared to $516,599 for the September 2010 period, an increase of $231,343 or approximately 45%. This increase was primarily due to higher expenses in certain expense categories, most notably officer salary and consulting fees of approximately $136,000 due to higher headcount; legal fees for patent filings and related prosecution of approximately $97,000; legal fees for due diligence associated with the BioMimetix Investment of approximately $21,000; minimum royalty payments due under the Bacterial License of $25,000; and offering costs of approximately $21,000 associated with an aborted equity financing conducted during the three months ended June 30, 2011. Offsetting these increases was a decrease in public and investor relations expense of approximately $31,000 and a decrease of approximately $29,000 related to an exploratory project for AAT biohazard indications that was incurred during the three months ended June 30, 2010. This project was discontinued in December 2010.

Research and development expenses — Research and development expenses for the September 2011 period were $255,875 as compared to $82,889 for the September 2010 period, an increase of $172,986. This increase was primarily due to an increase of approximately $113,000 in expense related to the Diabetes Clinical Trial as a result of four new patient infusions occurring in the September 2011 period and an increase of approximately $59,000 in expense related to the Viral SRA a result of terminating the Viral SRA and recording all estimated amounts due as of June 30, 2011.

Non-operating expenses — Non-operating expenses for the September 2011 period increased $475,873 as compared to the September 2010 period due to expenses recorded in the September 2011 period for the equity loss of BioMimetix of $335,928 and a charge in the amount of $140,959 for a modification of investor warrants originally issued during the fiscal year ended March 31, 2010.

Liquidity and Capital Resources

Our unaudited consolidated financial statements as presented in Item 1 of this report have been prepared in conformity with US GAAP, which contemplate our continuation as a going concern. However, the report of our independent registered public accounting firm on our consolidated financial statements, as of and for the year ended March 31, 2011, contains an explanatory paragraph expressing substantial doubt as to our ability to continue as a going concern. The “going concern” qualification resulted from, among other things, our development-stage status, no revenue recognized since inception, our net losses since inception and the contractual commitments due under our Diabetes Clinical Trial and SRAs. As of September 30, 2011, we remain a development stage company and our focus continues to be on raising capital to fund current operations and research development efforts, which could include future clinical trials on AAT indications. As of September 30, 2011, we had a deficit accumulated from inception of approximately $34.5 million, which included total non-cash charges from inception of approximately $27.8 million. These conditions raise substantial doubt as to our ability to continue as a going concern. Our unaudited consolidated financial statements contained in this report do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might be different should we be unable to continue as a going concern.

Private Placement

On June 10, 2011, we accepted subscription agreements related to the sale of “Units” in the 2011 Private Placement. Each “Unit” is comprised of one share of our common stock and one warrant to purchase one share of our common stock for a purchase price of $1.25 per Unit. Each Private Placement Warrant is exercisable at $2.00 per share until five years from the initial closing of the 2011 Private Placement. The net proceeds of the 2011 Private Placement will be used for general working capital purposes and research and development projects, and $2.0 million was used to purchase the equity interest in BioMimetix.

On June 10, June 27 and August 8, 2011, we conducted three closings under the 2011 Private Placement, pursuant to which we entered into subscription agreements for the purchase of 3,037,900 Units for an aggregate subscription price of $3.8 million. After deducting offering expenses including commissions and expenses paid to the placement agent, net proceeds to us from such sales totaled $3.44 million. Certain of our officers and directors purchased an aggregate of 100,000 Units in the 2011 Private Placement.

16

GVC Capital served as the placement agent for the 2011 Private Placement and earned a commission of 9% of the gross proceeds raised. In addition, we were obligated to sell for a nominal fee to GVC Capital, as the placement agent, warrants to purchase 9% of the total number of shares of our common stock sold in the 2011 Private Placement, which are exercisable at a price of $1.50 per share (the “2011 Private Placement PA Warrants”). The 2011 Private Placement PA Warrants expire five years from the date of the final closing of the 2011 Private Placement. We issued a total of 273,411 of 2011 Private Placement PA Warrants to GVC Capital in conjunction with the 2011 Private Placement. Two of our directors are Senior Managing Partners in GVC Capital.

At our option, we may call the 2011 Private Placement Warrants through June 10, 2016 by giving the holder notice of call upon 20 days written notice. Such notice may be given by us only within 10 days after our common stock has had a closing price of not less than $4.00 per share for 20 out of 30 consecutive trading days with trading volume in excess of 25,000 shares per day for that period of days.

Cash and Cash Equivalents

We consider all liquid investments purchased within 90 days of their original maturity to be cash equivalents. Our cash and cash equivalents at September 30, 2011, March 31, 2011 and September 30, 2010 were approximately $0.9 million, $0.3 million and $0.7 million, respectively.

Cash Flows from Operating Activities

For the September 2011 period, net cash used in operations was $807,127. The primary use of cash from operations was general and administrative expenses excluding share-based compensation, which totaled $747,942 and research and development expenses of $255,875. For this same period, the primary sources of cash from operations was a accrual recorded in the amount of $140,223 related to estimated costs to settle all obligations due under the Viral SRA and a net increase of $85,653 in accrued research and development costs related to the Diabetes Clinical Trial. For the September 2010 period, net cash used in operations was $1,056,140. The primary uses of cash from operations were general and administrative expenses excluding share-based compensation, which totaled $516,599, the initial prepayment of $365,000 related to the Diabetes Clinical Trial and research and development expense of $82,889.

Cash Flows from Investing Activities

For the September 2011 period, our cash used in investing activities was comprised of the $2.0 million investment in BioMimetix. For the September 2010 period, we did not generate or expend cash from investing activities.

Cash Flows from Financing Activities

For the September 2011 period, we generated $3.4 million of cash from financing activities from the 2011 Private Placement. This amount was net of offering costs of approximately $354,000. For the September 2011 period, we did not generate or expend cash from financing activities.

Anticipated Cash Commitments

As of September 30, 2011, we have obligations to complete the Diabetes Clinical Trial, which we estimate to be approximately $120,000 and to settle all amounts due to UCD under the termination of the Viral SRA, which we currently estimate to be approximately $140,000. Beginning in June 2011, we began to reduce our cash expenditures through a plan to reduce employee headcount, curtail patent prosecution in certain matters and terminate a research and development project that did not fit with our AAT commercial opportunities in the near term. We may enter into additional research and development projects and/or additional clinical trials in AAT indications that we believe are the most commercially viable in the near term, subject to raising additional capital from outside investors or through a potential strategic partnership with a pharmaceutical company.

17

We expect that the cash raised in the 2011 Private Placement will allow us to operate through our fiscal year ended March 31, 2012 based on current operating levels, however, we will likely need to engage in additional capital raising to operate beyond that period. We will also need to raise an additional $2.0 million by July 15, 2012 to allow us to purchase up to an aggregate 40% ownership in BioMimetix, should we elect to exercise the BioM Warrant in full.

We currently are pursuing various avenues to obtain additional capital including raising money in the equity markets and strategic partnerships with pharmaceutical companies. There can be no assurance that additional capital will be available to us on acceptable terms or at all. Failure to obtain additional capital will have a material adverse impact on our ability to continue to operate.

Critical Accounting Policies

We prepare our financial statements in accordance with US GAAP. Our significant accounting policies are disclosed in Note 2 to our consolidated financial statements contained in our 2011 Form 10-K. Those that are the most fundamental to the understanding our financial statements are our use of estimates, including the accounting for clinical trials and other research and development projects, the computation of share-based compensation and determination of fair value of our stock price used in those computations; the computation of other equity-based payments; and the capitalization of license agreements and impairment analysis of the capitalized license costs.

In addition and effective with this report, our critical accounting policies include the accounting for BioMimetix, which is a private company and related party. We do not hold a controlling financial interest in BioMimetix, but have the ability to exercise significant influence over its operating and financial policies. Based on these factors and our ownership of 28.1% of BioMimetix’s issued and outstanding shares of common stock, we accounted for BioMimetix under the equity method.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

There have been no material changes in qualitative and quantitative disclosures about market risk since our 2011 Form 10-K.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We are responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of September 30, 2011, and our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of that date.

Change in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting during the quarter ended September 30, 2011 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

18

PART II — OTHER INFORMATION.

Item 1. Legal Proceedings.

We are not a party to any material legal proceedings nor is our property the subject of any material legal proceedings.

Item 1A. Risk Factors.

There have been no material changes or updates to the risk factors previously disclosed in Item 1A. “Risk Factors” of our 2011 Form 10-K and our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2011.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

In September 2011, we sold for a nominal fee 273,411 common stock purchase warrants (the “2011 Private Placement PA Warrants”) to GVC Capital LLC (“GVC Capital”) as partial consideration for their services as the placement agent for the 2011 Private Placement. The 2011 Private Placement PA Warrants are exercisable at a price of $1.50 per share and carry a cashless exercise provision. Two of our directors are senior managing partners in GVC Capital. The securities were issued under Section 4(2) of the Securities Act of 1933, as amended.

Item 3. Defaults Upon Senior Securities.

None.

Item 5. Other Information.

None.

19

Item 6. Exhibits.

EXHIBIT #		DESCRIPTION
	3.1	Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Registration Statement on Form SB-2 filed on March 2, 2007)
	3.2	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on January 5, 2010)
	3.3	Articles of Amendment for Across America Financial Services, Inc. including Amendment to Articles of Incorporation of Across America Financial Services, Inc. (incorporated by reference to Exhibit 3.3 to the Registrant’s Current Report on Form 8-K filed on June 2, 2009)
	10.1	Stockholders’ Agreement by and among BioMimetix Pharmaceutical, Inc., Omni Bio Pharmaceutical, Inc. and certain investors, named therein, dated July 15, 2011 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on July 21, 2011)
	10.2	Stock Purchase Agreement by and between BioMimetix Pharmaceutical, Inc. and Omni Bio Pharmaceutical, Inc. dated July 15, 2011 (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on July 21, 2011)
	10.3	Warrant to Purchase Shares of Common Stock issued to Omni Bio Pharmaceutical, Inc. by BioMimetix Pharmaceutical, Inc. dated July 15, 2011 (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed on July 21, 2011)
	10.4	Letter of Employment by and between James Crapo and Omni Bio Pharmaceutical, Inc. dated July 15, 2011(incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed on July 21, 2011)
	31.1	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 #
	31.2	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 #
	32.1	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code #
101.INS		XBRL Instance Document**
101.SCH		XBRL Taxonomy Extension Schema Document**
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document**
101.LAB		XBRL Taxonomy Extension Label Linkbase Document**
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document**
101 DEF		XBRL Taxonomy Extension Definition Linkbase Document**

#	Filed with the Original Filing
**	Pursuant to Rule 406T of Regulation S-T, the information in Exhibit 101 is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 or the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

20

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	OMNI BIO PHARMACEUTICAL, INC.
November 9, 2011	By:	/s/ Robert C. Ogden
		Robert C. Ogden
		Chief Financial Officer (Principal Financial and Accounting Officer)

21

EX-31.1

Exhibit 31.1

SECTION 302 CERTIFICATION

I, James D. Crapo, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Omni Bio Pharmaceutical, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2011	/s/ James D. Crapo
	James Crapo
	Chief Executive Officer

EX-31.2

Exhibit 31.2

SECTION 302 CERTIFICATION

I, Robert C. Ogden, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Omni Bio Pharmaceutical, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2011	/s/ Robert C. Ogden
	Robert C. Ogden
	Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Omni Bio Pharmaceutical, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2011 (the “Report”), the undersigned, Chief Executive Officer and Chief Financial Officer of the Company, hereby certify that, to the best of our knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by this report.

Date: November 9, 2011	/s/ James D. Crapo
	James D. Crapo
	Chief Executive Officer
	/s/ Robert C. Ogden
	Robert C. Ogden
	Chief Financial Officer

XML

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2011	Mar. 31, 2011
Consolidated Balance Sheets [Abstract]
Preferred stock, par value	$ 0.1	$ 0.1
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	32,018,396	28,980,496
Common stock, shares outstanding	32,018,396	28,980,496

XML

Consolidated Statements Of Operations (USD $)	3 Months Ended		6 Months Ended		68 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011
Operating expenses:
General and administrative (including share-based compensation of $919,803, $2,376,849, $1,839,606 and $4,850,902, $16,167,157, respectively)	$ 1,271,348	$ 2,632,820	$ 2,587,548	$ 5,367,501	$ 20,571,364
Research and development	63,743	82,889	255,875	82,889	1,965,885
License fee - related party					5,615,980
Charge for common stock issued pursuant to license agreements					763,240
Total operating expenses	1,335,091	2,715,709	2,843,423	5,450,390	28,916,469
Loss from operations	(1,335,091)	(2,715,709)	(2,843,423)	(5,450,390)	(28,916,469)
Non-operating income (expenses):
Equity in loss of related party	(335,928)		(335,928)		(335,928)
Interest income (expense), net	970	1,278	1,648	3,634	(50,745)
Accretion expense on notes payable - related party				(3,000)	(56,125)
Charges for warrants issued in merger - related parties					(1,948,237)
Charge for warrants issued in private placement - related parties					(403,350)
Charges for modifications to warrants	(140,959)		(140,959)		(2,772,645)
Total non-operating income (expenses)	(475,917)	1,278	(475,239)	634	(5,567,030)
Net loss	$ (1,811,008)	$ (2,714,431)	$ (3,318,662)	$ (5,449,756)	$ (34,483,499)
Basic and diluted net loss per share	$ (0.06)	$ (0.10)	$ (0.11)	$ (0.19)
Weighted average shares outstanding - basic and diluted	31,920,918	28,042,982	30,748,871	28,022,974

XML

Document And Entity Information	6 Months Ended
	Sep. 30, 2011	Nov. 01, 2011
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2011
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2012
Entity Registrant Name	OMNI BIO PHARMACEUTICAL, INC.
Entity Central Index Key	0001389870
Current Fiscal Year End Date	--03-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		32,018,396

XML

Net Loss Per Share

6 Months Ended

Sep. 30, 2011

Net Loss Per Share [Abstract]

Net Loss Per Share

NOTE 4 – NET LOSS PER SHARE

Basic loss per share is computed based on the weighted average number of common shares outstanding during the period presented. Diluted earnings (loss) per share is computed using the weighted average number of common shares outstanding plus the number of common shares that would be issued assuming exercise or conversion of all potentially dilutive common shares. Potentially dilutive securities are excluded from the calculation when their effect would be anti-dilutive. For all periods presented in the consolidated financial statements, all potentially dilutive securities have been excluded from the diluted share calculations as they were anti-dilutive as a result of the net losses incurred for the respective periods. Accordingly, basic shares equal diluted shares for all periods presented. As of September 30, 2011 and September 30, 2010, potentially dilutive securities were comprised of 13,934,303 and 11,557,992 common stock purchase warrants, respectively.

XML

Consolidated Statements Of Cash Flows (USD $)	6 Months Ended		68 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,318,662)	$ (5,449,756)	$ (34,483,499)
Adjustments used to reconcile net loss to net cash used in operating activities:
Equity in loss of related party	335,928		335,928
Charge for warrant issued for purchase of license - related party			5,590,980
Common stock issued pursuant to license agreements			763,240
Share-based compensation	1,839,606	4,850,902	16,167,157
Charge for warrants issued in merger transaction - related parties			1,948,237
Charge for warrants issued in private placement transaction - related parties			403,350
Charges for modifications to warrants	140,959		2,772,645
Accretion expense - related parties		3,000	56,125
Depreciation and amortization	2,642	3,440	25,588
Contributed rent			19,740
Loss on disposal of equipment			2,444
Changes in operating assets and liabilities:
Prepaid clinical trial fee		(365,000)
Other current assets	(7,417)	(29,129)	(53,057)
Accounts payable	34,191	(37,985)	282,131
Accrued liabilities	(60,250)	(31,237)	(255,574)
Accrued research and development costs	85,653		130,389
Amount due under sponsored research agreement	140,223		140,223
Amounts due to related parties		(375)	207,632
Net cash used in operating activities	(807,127)	(1,056,140)	(5,946,321)
CASH FLOWS FROM INVESTING ACTIVITIES:
Equity investment in related party	(2,000,000)		(2,000,000)
Cash proceeds from reverse merger transactions			11,750
Purchase of licenses			(7,423)
Purchase of property and equipment			(35,401)
Net cash used in investing activities	(2,000,000)		(2,031,074)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from the sale of common stock and warrants	3,443,870		7,729,815
Proceeds from the issuance of notes payable to related party			825,000
Proceeds from the sale of common stock warrants			125,000
Proceeds from the exercise of common stock warrants			236,088
Net cash provided by financing activities	3,443,870		8,915,903
Net increase (decrease) in cash and cash equivalents	636,743	(1,056,140)	938,508
Cash and cash equivalents at beginning of period	301,765	1,802,366
Cash and cash equivalents at end of period	$ 938,508	$ 746,226	$ 938,508

XML

Investment In Biomimetix Pharmaceutical, Inc

6 Months Ended

Sep. 30, 2011

Investment In Biomimetix Pharmaceutical, Inc [Abstract]

Investment In Biomimetix Pharmaceutical, Inc

NOTE 6 – INVESTMENT IN BIOMIMETIX PHARMACEUTICAL, INC.

On July 15, 2011 for cash consideration of $2.0 million, we purchased an equity ownership in BioMimetix Pharmaceutical, Inc. ("BioMimetix") comprised of 250,000 shares of BioMimetix's common stock and a warrant (the "BioM Warrant") to purchase additional shares of BioMimetix's common stock (together the "BioM Investment"). The BioM Warrant is immediately exercisable and expires on July 15, 2012. If the BioM Warrant is fully exercised, which will require an additional $2.0 million cash investment, we will hold an aggregate 40% equity ownership interest in BioMimetix. The BioM Warrant may be exercised in whole or in part, and if in part, our diluted equity ownership upon exercise will be calculated as follows: (Cash Consideration Paid multiplied by 15% divided by $2,000,000) plus 25%. As of September 30, 2011, we owned 28.1% of BioMimetix's issued and outstanding shares.

Concurrent with the BioM Investment, Duke University entered into an exclusive licensing arrangement with BioMimetix (the "Duke License"), and as consideration, Duke University received 100,000 shares of BioMimetix's common stock. BioMimetix is a recently formed biopharmaceutical corporation and, as the exclusive licensee of the Duke License, intends to develop a new class of patented compounds for the treatment of various disease and health care treatment classifications including radiation toxicity during the treatment of cancer using radiation therapy.

Dr. James Crapo, our Chief Executive Officer, is the founder and a significant shareholder of BioMimetix and serves as its CEO and as a director. Under the terms of the BioMimetix stockholders' agreement, we have the right to appoint one individual, reasonably acceptable to Dr. Crapo, to serve on BioMimetix's board of directors. In addition, we received certain preemptive rights to purchase additional shares of BioMimetix and other protective rights relating to the BioM Investment.

We accounted for the BioM Investment using the equity method of accounting and recorded the BioM Investment at the purchase price of $2.0 million, which was deemed to be fair value. The purchase price exceeded our pro-rata share of BioMimetix's net assets and this difference of approximately $1.4 million was attributable to equity method goodwill, which is not amortized. For the three and six months ended September 30, 2011, we recorded a pro-rata net loss from BioMimetix of $335,928.

For the three and six months ended September 30, 2011, BioMimetix reported the following operating results:

Loss from continuing operations	$  (1,197,051)
Net loss and net loss attributable to investee	$  (1,195,902)

As of September 30, 2011, BioMimetix's balance sheet was comprised as follows:

Assets (all cash)	$  1,730,538
Liabilities	$  81,650
Stockholders' equity	$  1,648,888

XML

Share-Based Compensation

6 Months Ended

Sep. 30, 2011

Share-Based Compensation [Abstract]

Share-Based Compensation

NOTE 5 – SHARE-BASED COMPENSATION

All equity-based awards to employees, directors and consultants are recognized in the consolidated financial statements at the fair value of the award on the grant date. During the six months ended September 30, 2011, we did not grant or issue any equity-based awards.

Share-based compensation recorded for the three and six months ended September 30, 2011 and 2010 was as follows:

	Three Months Ended September 30,		Six Months Ended September 30,
	2011	2010	2011	2010
Employees, and directors	$       919,803	$     1,316,970	$    1,839,606	$     2,731,142
Outside consultants	-	1,059,879	-	2,119,760
	$      919,803	$     2,376,849	$   1,839,606	$    4,850,902

As of September 30, 2011, there was approximately $4.8 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements that is expected to be recognized over a weighted-average period of approximately 1.7 years.

A summary of activity related to warrants issued to employees, directors and consultants under share-based compensation agreements for the three months ended September 30, 2011 is as follows:

	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at March 31, 2011	3,243,000	$1.97
Granted	-	-
Exercised	-	-
Forfeited/expired/cancelled	-	-
Outstanding at September 30, 2011	3,243,000	$1.97	4.1	$     741,000
Vested and exercisable at September 30, 2011	2,863,000	$1.84	4.0	$     741,000

XML

Consolidated Statements Of Stockholders' Equity (USD $)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Deficit Accumulated During Development Stage [Member]	Total
Balances at Mar. 31, 2011		$ 28,980	$ 31,336,345	$ (31,164,837)	$ 200,488
Balance, shares at Mar. 31, 2011		28,980,496
Common stock and common stock purchase warrants sold in private placement offering, net of offering costs of $353,505 (June and August 2011 at $1.25 per unit)		3,038	3,440,832		3,443,870
Common stock and common stock purchase warrants sold in private placement offering, net of offering costs of $353,505 (June and August 2011 at $1.25 per unit), shares		3,037,900
Share-based compensation			1,839,606		1,839,606
Charge for modification to common stock purchase warrants sold in private placement offering in December 2009 and January 2010)			140,959		140,959
Net loss				(3,318,662)	(3,318,662)
Balances at Sep. 30, 2011		$ 32,018	$ 36,757,742	$ (34,483,499)	$ 2,306,261
Balance, shares at Sep. 30, 2011		32,018,396

XML

Overview And Basis Of Presentation

6 Months Ended

Sep. 30, 2011

Overview And Basis Of Presentation [Abstract]

Overview And Basis Of Presentation

NOTE 1 – OVERVIEW AND BASIS OF PRESENTATION

Overview

Omni Bio Pharmaceutical, Inc. ("Omni") is the licensee of patents and patent applications related to novel compositions of matter and methods of use for an existing FDA approved drug, Alpha-1 antitrypsin ("AAT"). We currently hold three licenses with the Regents of the University of Colorado ("RUC") in the areas of cellular transplantation, bacterial disorders and viral disorders. Our current licensed patent portfolio with RUC is comprised of 3 issued patents and 24 patent applications. We also hold a fourth license to a patent application for the treatment of diabetes with a privately-held company, Bio Holding, Inc. ("Bio Holding").

We are currently focusing on three indications for treatment using AAT: diabetes, complications due to graft rejection, also referred to as graft versus host disease ("GVHD"), and islet transplantation. To date, our business efforts have been largely dedicated to pursuing additional capital to fund Sponsored Research Agreements ("SRAs") with the University of Colorado Denver ("UCD") in indications covered under the license agreements with RUC and Bio Holding and to fund a human clinical trial in Type 1 diabetes. Since inception, we have not generated any revenues from our operations.

Basis of Presentation

The accompanying unaudited consolidated financial statements are comprised of Omni and its wholly-owned subsidiary, Omni Bio Operating, Inc., and have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the unaudited consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements, and reflect all adjustments, consisting only of normal, recurring adjustments, necessary for a fair presentation in accordance with US GAAP. The results of operations for interim periods presented are not necessarily indicative of the operating results for the full year. These unaudited consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2011 (the "2011 Form 10-K"). The balances as of March 31, 2011 are derived from our audited consolidated financial statements.

Except as the context otherwise requires, the terms "Company," "we," "our" or "us" means Omni and its wholly-owned subsidiary, Omni Bio Operating, Inc. ("Omni Bio").

Going Concern

The accompanying financial statements have been prepared in conformity with US GAAP, which contemplate our continuation as a going concern, whereby the realization of assets and liquidation of liabilities are in the ordinary course of business. However, the report of our independent registered public accounting firm on our consolidated financial statements, as of and for the year ended March 31, 2011, contains an explanatory paragraph expressing substantial doubt as to our ability to continue as a going concern. The "going concern" qualification resulted from, among other things, our development-stage status, no revenue recognized since inception, our net losses since inception and the outstanding and currently anticipated contractual commitments for research and development efforts and clinical trials. As of September 30, 2011, we remain a development stage company and our focus continues to be on raising capital to fund current operations and research and development efforts on AAT indications. As of September 30, 2011, we had a deficit accumulated from inception of $34.5 million, which included total non-cash charges from inception of approximately $27.8 million. These conditions raise substantial doubt as to our ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might be different should we be unable to continue as a going concern.

In June and August of 2011, we completed three closings of a private placement equity offering (the "2011 Private Placement") and raised approximately $3.44 million in net cash proceeds. See further discussion and disclosures in Note 2. We expect that the cash raised in the 2011 Private Placement will allow us to fund our operations through our fiscal year ended March 31, 2012 based on current operating levels, however, we will need to engage in additional capital raising to operate beyond that period. There is no assurance that we will be successful in raising additional capital on acceptable terms or at all. Failure to obtain additional capital may have a material adverse impact on our ability to continue our research and development efforts and fund our operating expenses beyond March 31, 2012.

Supplemental Disclosures of Non-Cash Investing and Financing Activities

	For the Six Months  Ended September 30,
	2011	2010
Accounts payable converted to common stock	$                -	$       49,982
Note payable – related party converted to common stock	$                -	$       25,000

Recently Issued Accounting Standard Updates

We have reviewed all of the FASB's Accounting Standard Updates through the filing date of this report and have concluded that none will have a material impact on our future consolidated financial statements.

XML

Private Placement Transaction

6 Months Ended

Sep. 30, 2011

Private Placement Transaction [Abstract]

Private Placement Transaction

NOTE 2 – PRIVATE PLACEMENT TRANSACTION

On June 10, 2011, we accepted subscription agreements related to the sale of "Units" in the 2011 Private Placement. Each "Unit" is comprised of one share of our common stock and one warrant to purchase one share of our common stock for a purchase price of $1.25 per Unit.Each warrant in the Unit (the "2011 Private Placement Warrants") is exercisable at $2.00 per share until five years from the initial closing of the 2011 Private Placement.The net proceeds of the 2011 Private Placement will be used for general working capital purposes and research and development projects, and $2.0 million was used to purchase an equity interest in a private biotech company that is a related party. See further discussion in Note 6.

On June 10, 2011, we conducted the initial closing under the 2011 Private Placement, pursuant to which we entered into subscription agreements for the purchase of 2,463,900 Units for an aggregate subscription price of $3,079,875. After deducting offering expenses, including commissions and expenses paid to the placement agent, net proceeds to us from such sales totaled approximately $2,797,000. Certain of our officers and directors purchased an aggregate of 50,000 Units in the initial closing of the 2011 Private Placement.

On June 27, 2011, we conducted a second closing under the 2011 Private Placement, pursuant to which we entered into subscription agreements for the purchase of 338,000 Units for an aggregate subscription price of $422,500. After deducting offering expenses including commissions and expenses paid to the placement agent, net proceeds to us from such sales totaled approximately $378,000. Certain of our officers and directors purchased an aggregate of 50,000 Units in the second closing of the 2011 Private Placement.

On August 8, 2011, we completed the final closing for the 2011 Private Placement, pursuant to which we accepted subscription agreements for the purchase of 236,000 Units for an aggregate subscription price of $295,000. After deducting offering expenses, including commissions and expenses paid to the placement agent, net proceeds to us from such sales totaled approximately $266,000.

GVC Capital LLC ("GVC Capital") served as the placement agent for the 2011 Private Placement and earned a cash commission of 9% of the gross proceeds raised. In addition, we were obligated to sell for a nominal fee to GVC Capital, as the placement agent, warrants to purchase 9% of the total number of shares of our common stock sold in the 2011 Private Placement, which are exercisable at a price of $1.50 per share (the "2011 Private Placement PA Warrants"). The 2011 Private Placement PA Warrants expire five years from the date of the final closing of the 2011 Private Placement. We issued a total of 273,411 of 2011 Private Placement PA Warrants to GVC Capital in conjunction with the three closings of the 2011 Private Placement. Two of our directors are senior managing partners in GVC Capital.

At our option, we may call the 2011 Private Placement Warrants through June 10, 2016 by giving the holder notice of call upon 20 days written notice.  Such notice may be given by us only within 10 days after our common stock has had a closing price of not less than $4.00 per share for 20 out of 30 consecutive trading days with trading volume in excess of 25,000 shares per day for that period of days.

XML

Contractual Commitments

6 Months Ended

Sep. 30, 2011

Contractual Commitments [Abstract]

Contractual Commitments

NOTE 3 – CONTRACTUAL COMMITMENTS

Type 1 Diabetes Clinical Trial

On June 7, 2010, we executed an Investigational Site Agreement (the "ISA"), whereby we agreed to fund a two-year clinical study to evaluate AAT in the treatment of patients with Type 1 diabetes (the "Diabetes Clinical Trial"). The Diabetes Clinical Trial was initially to include 15 patients.  In October 2011, we elected to reduce the size of the Diabetes Clinical Trial to 12 patients.  Based on the reduction of patients, our remaining obligations for the Diabetes Clinical Trial are approximately $120,000.   For the six months ended September 30, 2011, we recorded approximately $113,000 of research and development expense related to the Diabetes Clinical Trial based on four new patients infused during this period.

Viral Disorders SRA

On August 18, 2010, we entered into an SRA with RUC for UCD to perform studies to determine the biological activity of AAT as an inhibitor of influenza (the "Viral SRA"). We were required to make quarterly payments over a two-year period to UCD, which totaled approximately $440,000. As of September 30, 2011, we had paid UCD approximately $110,000.

On June 8, 2011, we gave written notice to RUC terminating the Viral SRA. In July 2011, we received acknowledgment from UCD of our termination letter related to the Viral SRA, and based on discussions related thereto, we have estimated and recorded a liability in the amount of $140,000 for settlement of all obligations due under the Viral SRA. This liability is represented as of September 30, 2011 under the caption "Amount due under sponsored research agreement" on our unaudited consolidated balance sheet included in this report.

Diabetes SRA

On September 3, 2010, we executed an SRA with UCD in the area of diabetes (the "Diabetes SRA").  The Diabetes SRA was executed pursuant to a license agreement for the treatment of diabetes (the "Diabetes License") that we executed in 2009 with Bio Holding. The total amount due under the Diabetes SRA is $88,000, of which all has been paid as of September 30, 2011.

XML

Consolidated Statements Of Operations (Parenthetical) (USD $)	3 Months Ended		6 Months Ended		68 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011
Consolidated Statements Of Operations [Abstract]
Share-based compensation	$ 919,803	$ 2,376,849	$ 1,839,606	$ 4,850,902	$ 16,167,157

XML

Consolidated Statements Of Stockholders' Equity (Parenthetical) (USD $)	6 Months Ended
	Sep. 30, 2011
Consolidated Statements Of Stockholders' Equity [Abstract]
Common stock and common stock purchase warrants sold in private placement offering cost	$ 353,505
Common stock and common stock purchase warrants sold in private placement offering, per unit	$ 1.25

XML

Consolidated Balance Sheets (USD $)	Sep. 30, 2011	Mar. 31, 2011
ASSETS
Cash and cash equivalents	$ 938,508	$ 301,765
Other current assets	50,958	43,541
Total current assets	989,466	345,306
Equity investment in related party	1,664,072
Intangible assets, net	59,289	61,931
Total long-term assets	1,723,361	61,931
TOTAL ASSETS	2,712,827	407,237
LIABILITIES & STOCKHOLDERS' EQUITY
Accounts payable	75,954	41,763
Amount due under sponsored research agreement	140,223
Accrued research and development costs	130,389	44,736
Accrued liabilities	56,250	116,500
Amounts due to related parties	3,750	3,750
Total current liabilities	406,566	206,749
Commitments and Contingencies (Notes 1 and 3)
Stockholders' equity:
Preferred stock, $0.10 par value, 5,000,000 shares authorized, -0- shares issued and outstanding
Common stock, $0.001 par value; 200,000,000 shares authorized; 32,018,396 and 28,980,496 shares issued and outstanding, respectively	32,018	28,980
Additional paid-in capital	36,757,742	31,336,345
Deficit accumulated during the development stage	(34,483,499)	(31,164,837)
Total stockholders' equity	2,306,261	200,488
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 2,712,827	$ 407,237